Drug Type Bispecific antibody |
Synonyms- |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), nectin-4 inhibitors(Nectin-4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Preclinical | Guatemala | 16 Jul 2024 | |
Head and Neck Neoplasms | Preclinical | Guatemala | 16 Jul 2024 | |
Non-Small Cell Lung Cancer | Preclinical | Guatemala | 16 Jul 2024 | |
Pancreatic Cancer | Preclinical | Guatemala | 16 Jul 2024 | |
Triple Negative Breast Cancer | Preclinical | Guatemala | 16 Jul 2024 |